<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Isosorbide mononitrate: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Isosorbide mononitrate: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Isosorbide mononitrate: Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_patient" data-topicid="10776" href="/d/html/10776.html" rel="external">see "Isosorbide mononitrate: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list canbnlist drugH1Div drugBrandNames" id="F52867279"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-ISMN;</li>
<li>Imdur;</li>
<li>PMS-ISMN;</li>
<li>PRO-ISMN-60</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F185126"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antianginal Agent;</li>
<li>
                        Vasodilator</li></ul></div>
<div class="block doa drugH1Div" id="F185083"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="dc09e27a-efe5-434f-85df-59b0c70de3fd">Angina, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Angina, prevention:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>For prevention of recurrent angina, may use in combination with other anti-anginal therapy (eg, beta-blocker) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25249585','lexi-content-ref-23256914']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25249585','lexi-content-ref-23256914'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release: <b>Oral:</b> 20 mg twice daily; administer second dose at least 7 hours after the first dose (eg, 8 AM and 3 PM) to decrease tolerance development; patients with small stature may initiate therapy with 5 mg twice daily and titrate to at least 10 mg twice daily in first 2 to 3 days of therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">Extended release: <b>Oral:</b> Initial: 30 to 60 mg once daily in the morning; may titrate after several days to 120 mg once daily; rarely, 240 mg once daily may be required.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991672"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> Mild to severe impairment: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3732374','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3732374','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Moderately dialyzable (AUC<sub>0-8 </sub>decreased 30% with a 4-hour dialysis session (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3622599']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3622599'])">Ref</a></span>)): No supplemental dose or dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Not significantly dialyzed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3622599']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3622599'])">Ref</a></span>): No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988986"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary.</p></div>
<div class="block doe drugH1Div" id="F185084"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing; initiate with lowest recommended dose. </p></div>
<div class="block arsc drugH1Div" id="F58280474"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Headaches</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">The use of nitrates, including isosorbide mononitrate, commonly results in <b>headache</b>; <b>migraine</b> or <b>cluster headache</b> may also occur (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20331608','lexi-content-ref-2506059','lexi-content-ref-11606504','lexi-content-ref-11740135','lexi-content-ref-10393392','lexi-content-ref-22849337','lexi-content-ref-9727544','lexi-content-ref-8682597']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20331608','lexi-content-ref-2506059','lexi-content-ref-11606504','lexi-content-ref-11740135','lexi-content-ref-10393392','lexi-content-ref-22849337','lexi-content-ref-9727544','lexi-content-ref-8682597'])">Ref</a></span>). The severity of headaches ranges from mild to severe and, depending on the etiology, may decrease in both frequency and intensity with continued use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11037739','lexi-content-ref-10188765','lexi-content-ref-6443349','lexi-content-ref-11409656']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11037739','lexi-content-ref-10188765','lexi-content-ref-6443349','lexi-content-ref-11409656'])">Ref</a></span>); however, some patients require symptomatic treatment of the headache and/or discontinuation of nitrate therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33850272','lexi-content-ref-8482456','lexi-content-ref-25790943']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33850272','lexi-content-ref-8482456','lexi-content-ref-25790943'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: There are multiple proposed mechanisms. Immediate headaches are thought to be a result of vasodilation caused by nitric oxide release (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20331608','lexi-content-ref-11037739','lexi-content-ref-18521538']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20331608','lexi-content-ref-11037739','lexi-content-ref-18521538'])">Ref</a></span>); whereas migraine may occur as a result of vasodilation, calcitonin gene-related peptide or glutamate release, and/or ion channel function changes associated with cyclic guanosine monophosphate or S-nitrosylation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20331608','lexi-content-ref-11037739']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20331608','lexi-content-ref-11037739'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Rapid; immediate headaches may appear within minutes to hours of administration and last for several hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20331608','lexi-content-ref-6443349']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20331608','lexi-content-ref-6443349'])">Ref</a></span>); migraine may occur within hours of administration and last for several hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20331608']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20331608'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Migraine is more common in patients with a prior history or predisposing risk factors for migraine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20331608']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20331608'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher initial dose and/or rapid dose titration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8686962','lexi-content-ref-10188765','lexi-content-ref-1760824']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8686962','lexi-content-ref-10188765','lexi-content-ref-1760824'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypotension and bradycardia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Isosorbide mononitrate administration may result in <b>hypotension</b> or <b>orthostatic hypotension</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11606504','lexi-content-ref-10188765','lexi-content-ref-22849337','lexi-content-ref-19349588','lexi-content-ref-8509566']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11606504','lexi-content-ref-10188765','lexi-content-ref-22849337','lexi-content-ref-19349588','lexi-content-ref-8509566'])">Ref</a></span>); paradoxical <b>bradycardia</b> and <b>exacerbation of angina</b>
<b>pectoris </b>may also occur. Tolerance may develop to the effect on blood pressure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10188765']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10188765'])">Ref</a></span>); however, hypotension can be severe (even at small doses) and require treatment discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33850272','lexi-content-ref-8482456','lexi-content-ref-25790943']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33850272','lexi-content-ref-8482456','lexi-content-ref-25790943'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; related to the pharmacologic action (vasodilation) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10188765']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10188765'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Rapid; decrease in blood pressure occurs within hours of administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8055999','lexi-content-ref-8509566','lexi-content-ref-12574098']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8055999','lexi-content-ref-8509566','lexi-content-ref-12574098'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Consumption of ethanol may exacerbate orthostatic hypotension</p>
<p style="text-indent:-2em;margin-left:6em;">• Upright position</p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant use of phosphodiesterase-5 inhibitors (eg, sildenafil, tadalafil, vardenafil) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23917809','lexi-content-ref-15533876']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23917809','lexi-content-ref-15533876'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Hypovolemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-822962']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-822962'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Intracranial pressure increased</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Nitrates, especially use of IV nitrates (eg, nitroprusside, nitroglycerin), may precipitate or aggravate increased intracranial pressure and subsequently may worsen clinical outcomes in patients with neurologic injury (eg, intracranial hemorrhage, traumatic brain injury) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18514825']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18514825'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b></b>
<i>Mechanism</i>: Dose-related; related to the pharmacologic action (vasodilation resulting in decreased cerebral blood flow) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18514825']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18514825'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F185051"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Nervous system: Dizziness (4% to 11%), headache (13% to 57%)<span class="lexi-table-link-container"> (<a aria-label="Headache table link" class="lexi-table-link" data-table-id="lexi-content-headache" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-headache')">table 1</a>)</span><span class="table-link" style="display:none;">Headache</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Headache" frame="border" id="lexi-content-headache" rules="all">
<caption style="text-align:center;">
<b>Isosorbide Mononitrate: Adverse Reaction: Headache</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Isosorbide Mononitrate)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Isosorbide Mononitrate)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">57%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">15%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">240 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">ER tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">65</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">96</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">51%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">15%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">60 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">ER tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">102</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">96</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">42%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">15%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">120 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">ER tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">65</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">96</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">38%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">15%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">30 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">ER tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">60</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">96</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">35%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">20 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">159</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">160</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">17%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">54</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">160</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10 mg twice daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">52</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">160</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Abnormal heart sounds (≤5%), acute myocardial infarction (≤5%), atrial arrhythmia (≤5%), atrial fibrillation (≤5%), bradycardia (≤5%), bundle branch block (≤5%), cardiac arrhythmia (≤5%), chest pain (2%), ECG abnormality (Q wave: ≤5%), edema (≤5%), exacerbation of angina pectoris (≤5%), extrasystoles (≤5%), flushing (2%), heart failure (≤5%), heart murmur (≤5%), hypertension (≤5%), hypotension (≤5%), intermittent claudication (≤5%), palpitations (≤5%), tachycardia (≤5%), varicose veins (≤5%), ventricular tachycardia (≤5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Abnormal hair texture (≤5%), acne vulgaris (≤5%), cutaneous nodule (≤5%), diaphoresis (≤5%), leg ulcer (≤5%), pruritus (2%), skin rash (≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased libido (≤5%), hot flash (≤5%), hyperuricemia (≤5%), hypokalemia (≤5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (2%), constipation (≤5%), diarrhea (2%), dyspepsia (≤5%), flatulence (≤5%), gastric ulcer (≤5%), gastric ulcer with hemorrhage (≤5%), gastritis (≤5%), glossitis (≤5%), hemorrhoids (≤5%), loose stools (≤5%), melena (≤5%), nausea (3%), vomiting (≤5%), xerostomia (≤5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Atrophic vaginitis (≤5%), impotence (≤5%), mastalgia (≤5%), urinary tract infection (≤5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Hypochromic anemia (≤5%), purpuric disease (≤5%), thrombocytopenia (≤5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (≤5%), increased serum aspartate aminotransferase (≤5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Bacterial infection (≤5%), candidiasis (≤5%), viral infection (≤5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety (≤5%), asthenia (≤5%), confusion (≤5%), depression (≤5%), drowsiness (≤5%), emotional lability (2%), fatigue (4%), hypoesthesia (≤5%), insomnia (≤5%), lack of concentration (≤5%), malaise (≤5%), migraine (≤5%), myasthenia (≤5%), nervousness (≤5%), neuritis (≤5%), nightmares (≤5%), pain (4%), paresis (≤5%), paresthesia (≤5%), rigors (≤5%), tremor (≤5%), vertigo (≤5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (≤5%), back pain (≤5%), musculoskeletal pain (≤5%), myalgia (≤5%), myositis (≤5%), shoulder stiffness (frozen shoulder: ≤5%), tendinopathy (≤5%), torticollis (≤5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blepharoptosis (≤5%), conjunctivitis (≤5%), photophobia (≤5%), visual disturbance (≤5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Otalgia (≤5%), perforated tympanic membrane (≤5%), tinnitus (≤5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Nephrolithiasis (≤5%), polyuria (≤5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchitis (≤5%), bronchospasm (≤5%), cough (≤5%), dyspnea (≤5%), flu-like symptoms (≤5%), increased bronchial secretions (≤5%), increased cough (2%), nasal congestion (≤5%), pharyngitis (≤5%), pneumonia (≤5%), pulmonary infiltrates (≤5%), rales (≤5%), rhinitis (≤5%), sinusitis (≤5%), upper respiratory infection (1% to 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (≤5%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pallor</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Increased thirst, weight loss</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia, bitter taste</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Prostatic disease</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Cerebrovascular accident, restlessness</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Muscle cramps, neck pain</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Amblyopia</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Asthma</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Orthostatic hypotension (Mussi 2009), syncope (Mussi 2009)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Cluster headache (Bagdy 2010)</p></div>
<div class="block coi drugH1Div" id="F185066"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to isosorbide mononitrate, other nitrates or nitrites, or any component of the formulation; concurrent use with phosphodiesterase-5 (PDE-5) inhibitors (sildenafil, tadalafil, or vardenafil) or riociguat.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Acute circulatory failure associated with marked hypotension (shock and states of collapse); postural hypotension; myocardial insufficiency due to obstruction (eg, in the presence of aortic or mitral stenosis or of constrictive pericarditis); increased intracranial pressure; severe anemia.</p></div>
<div class="block war drugH1Div" id="F185048"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery or driving).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Not recommended for use in patients with acute myocardial infarction (MI) or heart failure (has not been studied). Use with caution in volume depletion and moderate hypotension, and with extreme caution with inferior wall MI and suspected right ventricular infarctions. The Canadian labeling contraindicates use in acute circulatory failure associated with marked hypotension, postural hypotension, and myocardial insufficiency due to obstruction (eg, in the presence of aortic or mitral stenosis or of constrictive pericarditis).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypertrophic cardiomyopathy with left ventricular outflow tract obstruction: Avoid use in patients with hypertrophic cardiomyopathy with left ventricular outflow tract obstruction; nitrates may reduce preload, exacerbating obstruction and cause hypotension or syncope and/or worsening of heart failure (AHA/ACC [Ommen 2021]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• PDE-5 inhibitors: Avoid concurrent use with PDE-5 inhibitors (eg, sildenafil, tadalafil, vardenafil). When nitrate administration becomes medically necessary, may administer nitrates only if 24 hours have elapsed after use of sildenafil or vardenafil (48 hours after tadalafil use) (O’Connor 2010).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage forms related issues:</b></p>
<p style="text-indent:-2em;margin-left:4em;">• Extended-release tablets: Empty matrix "ghosts" (tablets) may pass in patients via colostomy or in the stool; this is of no concern.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Extended-release: Not intended for the immediate relief of acute attacks of angina pectoris.</p>
<p style="text-indent:-2em;margin-left:4em;">• Tolerance: Appropriate dosing intervals are needed to minimize tolerance development. Tolerance can only be overcome by short periods of nitrate absence from the body. Dose escalation does not overcome this effect.</p></div>
<div class="block foc drugH1Div" id="F185059"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg, 20 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release 24 Hour, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 30 mg, 60 mg, 120 mg</p></div>
<div class="block geq drugH1Div" id="F185044"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F185068"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, 24-hour</b> (Isosorbide Mononitrate ER Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $0.52 - $3.35</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">60 mg (per each): $0.54 - $4.28</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">120 mg (per each): $0.76 - $8.80</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Isosorbide Mononitrate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $0.85</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $0.89</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867280"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release 24 Hour, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Imdur: 60 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 60 mg</p></div>
<div class="block adm drugH1Div" id="F185063"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Do not administer around-the-clock. IR tablet should be scheduled twice daily with doses 7 hours apart (8 AM and 3 PM); administer ER tablet once daily in the morning upon rising with a half-glassful of fluid. Do not chew or crush ER tablets; may be divided in half. Due to insoluble matrix embedding, ER tablets that are scored may be split (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10188765']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10188765'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Bariatric surgery: Tablet, extended release: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. Scored tablets may be cut in half. Alternatively, may switch to IR formulation.</p></div>
<div class="block use drugH1Div" id="F185062"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Angina pectoris, prevention:</b> Treatment (immediate-release only) and prevention of angina pectoris caused by coronary artery disease. <b>Note: </b>The onset of action of oral isosorbide mononitrate is not sufficiently rapid for this product to be useful in aborting an acute anginal episode.</p></div>
<div class="block mst drugH1Div" id="F185134"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Imdur may be confused with Imuran, Inderal LA, K-Dur</p>
<p style="text-indent:-2em;margin-left:4em;">Monoket may be confused with Monopril</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F185121"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F185053"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): May enhance the vasodilatory effect of Vasodilators (Organic Nitrates).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapoxetine: May enhance the orthostatic hypotensive effect of Vasodilators (Organic Nitrates).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapsone (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Local Anesthetics: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Vasodilators (Organic Nitrates).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitric Oxide: May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: May enhance the vasodilatory effect of Vasodilators (Organic Nitrates).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rilmenidine: Vasodilators (Organic Nitrates) may enhance the hypotensive effect of Rilmenidine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Riociguat: Vasodilators (Organic Nitrates) may enhance the hypotensive effect of Riociguat. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rosiglitazone: Vasodilators (Organic Nitrates) may enhance the adverse/toxic effect of Rosiglitazone. Specifically, a greater risk of ischemia and other adverse effects has been associated with this combination in some pooled analyses. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Nitrite: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Sodium Nitrite. Combinations of these agents may increase the likelihood of significant methemoglobinemia. <i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F11593066"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Adverse events have been observed in some animal reproduction studies.</p>
<p style="text-indent:0em;margin-top:2em;">Nitric oxide donors, such as isosorbide, have been evaluated for cervical ripening and induction of labor (Abu-Zaid 2022; Ghosh 2016); however, use of isosorbide mononitrate is not currently recommended for this indication (ACOG 2009; NICE 2021). Nitric oxide donors have also been evaluated for the prevention of preterm birth (Duckitt 2014; Wilson 2022); additional study is needed for this indication and use is not currently recommended (McDougal 2023; WHO 2022).</p></div>
<div class="block brc drugH1Div" id="F20681079"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if isosorbide mononitrate is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">The manufacturer recommends that caution be exercised when administering isosorbide mononitrate to patients who are breastfeeding.</p></div>
<div class="block mop drugH1Div" id="F185057"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Blood pressure, heart rate</p></div>
<div class="block pha drugH1Div" id="F185047"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Nitroglycerin and other nitrates form free radical nitric oxide. In smooth muscle, nitric oxide activates guanylate cyclase which increases guanosine 3’5’ monophosphate (cGMP) leading to dephosphorylation of myosin light chains and smooth muscle relaxation. Produces a vasodilator effect on the peripheral veins and arteries with more prominent effects on the veins. Primarily reduces cardiac oxygen demand by decreasing preload (left ventricular end-diastolic pressure); may modestly reduce afterload; dilates coronary arteries and improves collateral flow to ischemic regions.</p></div>
<div class="block phk drugH1Div" id="F185065"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Onset of action: 30 to 45 minutes (Thadani 1987)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Duration: Immediate release: ≥6 hours (Thadani 1987); Extended release: ≥12 to 24 hours (Anderson 2007)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Rapid and complete</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: V<sub>d</sub>: ~0.6 L/kg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: &lt;5%</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Hepatic</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Bioavailability: ~100%</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: 5 to 6 hours (Thadani 1987) </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak, plasma: 30 to 60 minutes</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Predominantly urine (2% as unchanged drug); feces (1%) </p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F185069"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Apo Ismn | Elantan | Imdur | Ismo | Mono mack | Monoclair | Monotrate</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Cilatron | Cilatron ap | Isosorbide 5-mononitrato gen med | Medocor | Medocor ap | Misordil | Monoket | Monotrin</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Elantan | Ismn | Isomonat | Isosorbidmononitrat 1a pharma gmbh | Isosorbidmononitrat genericon pharma | Isosorbidmononitrat hexal pharma | Mono-mack | Monoket | Myocardon mono | Olicardin</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apo isosorbide mononitrate | Arsorb | Cm isosorb mononit | Duride | Genrx isosorbide mononitrate | Imdur | Imtrate | Isobide mr | Isomonit | Isosorbide an | Isosorbide mononitrate-bc | Isosorbide pfizer | Isosorbide ps | Monodur | Tw isosorb mononit</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">A-Card | Angifix | Esmo | Imocard | Iso | Monate | Monis | Monit | Moniten | Monocard | Monocinque | Monocontin | Monotrate | Pentacard | Unicard</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Pentacard | Promocard</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Isosorbe | Monisid | Monodilat | Neosorbid | Olicard</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Cincordil | Coronar | Lfm mononitrato de isossorbida | Monocordil | Mononitrato de isossorbida | Mononitrato de isossorbida biolab gen | Vexell</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Ismo</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Ismo | Medocor | Mono Pack</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Ai di mo ni | Ai fu ning | Ai si mo | Chen gong zaijia | Danxiao | De mai ning | Detrilin | Elantan | Etimonis | Imdur | Is 5 mono | Ismo | Isomonit | Jin xin tai | Kai wei fu | Li wei | Li zhu xin le | Lu nan xin kang | Mono mack | Monotrate | Pentacard | Rui de ming | Shan su | Shu bi lai te | Suo ni te | Xin kang | Xin le | Xin tai | Ya xu | Yi bei te | Yi mai qing | Yi suo man | Yi xin jian | Zai cheng | Zai jia</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Cardalol | Cincordil | Imodur | Monis</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Elantan | Imdur | Ismn al | Isomonat | Isostenase | Mono mack | Monosan | Monosor | Monostenase | Monotab | Olicard | Sorbimon</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Coleb | Coleb-duriles | Conpin | Corangin | Duramonitat | Elan | Elantan | Is 5 mono | Ismanton | Ismn | Ismn 1a pharma | Ismn abz | Ismn al | Ismn basics | Ismn klast | Ismn Sandoz | Ismn stada | Ismn Temmler | Ismn von CT | Ismo | Ismonoreal | Isomon | Isomonit | Isosorbid mononitrate | Moni biochemie | Moni sanorania | Monit Puren | Mono | Mono 5 Wolff | Mono 5-Wolff | Mono acis | Mono mack | Mono Maycor | Mono sigma | Mono wolff | Mono-corax | Monobeta | Monoclair | Monolong | Mononitrat | Monopur | Monostenase | Olicard | Orasorbil | Sigacora | Turimonit</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Farmidur</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Angicor | Elantan | Ismo | Isocard | Isonitril | Medocor | Medocor ap | Mono Pack | Monobide | Monobide AP | Monocinque | Nitricor | Pectocor</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Elantan | Ismo | Medocor | Monobide | Monomack</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Effox | Elantan | Imdur | Is 5 mono-ratiopharm | Ismn stada | Isomonit | Isosorbide mononitrate vitabalans | Mono mack | Monolong | Monosan | Olicard</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Angiofox | Cardioguard m | Corangin | Effox | Imdur | Ismn | Ismn stada | Ismo | Isosorbide | Mono mack | Mono mak depot | Monocard</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Cardionil | Cardiovas | Coronur | Dolak | Isonitril | Mononitr isosorb normon | Mononitr isosorb ratiopharm | Olicard | Percorina | Pertil | Titrane | Uniket</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Imdur | Isangina | Ismexin | Ismox | Isosor | Monoket | Monomack | Ormox | Ormox od</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Monicor lp</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Angeze | Angitate | Carmil | Carmil xl | Chemydur | Cibral | Dynamin | Dynamin xl | Elantan | Eumon | Imdur | Imo la | Isib | Ismo | Isodur | Isomel | Isosorb mono | Isosorbide mononitrate cox | Isotard | Ketanodur | Mcr | Medomil | Modisal | Monit | Mono Cedocard | Monodur | Monomax | Monomil | Monomil xl | Monosorb | Nyzamac sr | Phasonit la50 | Relosorb XL | Tardisc xl | Trangina xl | Xismox | Zemon</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Angioval | G dil | Imdur | Isomon | Monoginal | Monoket | Monorythm | Monosordil | Nitramin | Nitrilan | Procardol</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo Ismn | Coxine | Elantan | Imdex | Imdur | Ismo | Mono mack | Monocinque</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Cardox | ISMN Genericon | ISMN Jadran | Isocard | Olicard</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Cardisorb | Ismn-aliud | Ismn-alkaloida | Isospan | Mono mack | Olicard | Rangin | Sorbimon</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Cardismo | Elantan | Imdur | Imocard | Ismo | Isomonit | Monecto | Mono mack | Pentacard</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Elantan | Imdur | Isomel | Isomonit | Sormon</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Monocord | Monolong | Mononit</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">5-mono | Angicor | Angifree | Angimon | Anginex | Angison | Angitab | Angitrit | Angivas | Difurate | Difutrate | Ihd | Imdur | Imnit | Insocalm | Isbid | Ismo | Isobax OD | Isocor | Isomeg | Isomin | Isonorm | Isotec | Monet | Monex | Monicor | Monit | Monit-od | Monn | Mono isordil | Monobid | Monocontin | Monomen | Monopark | Monosorbitrate | Monotrace | Monotrate | Natriem | Nican-CR | Nitrofirst | Nitrofix | Nitrovas | Olvisol | Solotrate | Sorb | Sormo | Synotrate | Vasodil | Vasonit | Vasotrate</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Duronitrin | Elan | Ismo | Isosorbide | Isosorbide eg | Isosorbide Mononitrato | Isosorbide mononitrato mylan generics | Isosorbide Sandoz | Kiton | Leicester | Monocinque | Monoket | Nitrex | Vasdilat</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Elantan | Ismo | Mono mack</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Airocool | Aislar | Banreel | Cardis | Isomonit | Isonitoll | Itorol | Soprerole | Soprerole yamakawa | Taisirol</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Imdur | Monicor | Mono mak | Monocontin | Monotrate</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Caso | Elantan | Eloton | Elroton | Elroton sr | Erantan | Imdur | Ismo | Isobid | Isoby retard | Isonite | Isotril | Monomax | Monosol</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Imdur | Monomack</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Elantan | Mono mack | Monocinque</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Elantan | Imdur | Is 5 mono | Ismn | Isomonit | Isosorbide mononitrate vitabalans | Monisid | Mono mack | Monolong | Mononit | Monosan | Olicard</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Elantan | Imdur | Isomonit | Mono mack</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Cardionil | Effox | Elantan | Imdur | Is 5 mono | Ismn | Isomonit | Isosorbide mononitrate vitabalans | Monisid | Mono mack | Monolong | Mononit | Monosan | Olicard</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Corangin | Mononitril</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Elantan | Elantan retard | Imdur | Isosorbida | Kenbrid | Mono mack | Monocorat | Monocorat depot | Monomack</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Duride | Elantan | Imdex | Imdur | Ismn | Ismo | Isomonit</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Isosorbide Mononitraat Actavis | Isosorbide Mononitraat Merck | Isosorbide mononitraat retard rph | Isosorbide-5-mononitraat Accord | Isosorbide-5-Mononitraat FLX | Isosorbidemononitraat | Isosorbidemononitraat A | Isosorbidemononitraat Actavis | Isosorbidemononitraat CF | Isosorbidemononitraat Gf | Isosorbidemononitraat Katwijk | Isosorbidemononitraat Merck | Isosorbidemononitraat PCH | Isosorbidemononitraat sandoz | Mono Cedocard | Mono-cedocard | Monocedocard | Promocard</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Imdur | Ismo | Ismo retard | Isomex | Isosorbid nycomed | Isosorbidmononitrat | Isosorbidmononitrat aliud | Monoket</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Duride | Imdur | Imtrate | Ismo</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Elantan | Izonit m | Monomack | Mononit</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Angistad | Elantan | Imdur | Ismn natrapharm | Ismo | Isomonit | Isonate | Isorbide | Isormed | Isotrate | Monis | Mono mack | Monobid | Monosorb | Monovas | Montra | Solotrate | Vasotrate</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Alsorbide | Corlet | Elanton | Flo | Imdur | Ismo | Ismo retard | Isomon | Isorate | Isotab | Isotime | Isotrate | Monis | Monit | Mono-card | Monotrate | Savdil | Sequence | Sorbimon | Vasocord</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Effox | Elantan | Isomonit | Isosorbide mononitrate vitabalans | Izonit | Mono mack | Mono tad | Monocard | Mononit | Olicard</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Imdur | Ismo | Isosorbide mononite | Monoket</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Amplexol | Imdur | Ismo | Monoket | Mononitrato de isossorbida | Mononitril | Monopront | Orasorbil</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Medocor | Medocor ap | Mni</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Effox | Effox 20 | Isosorbid mononitrat | Isosorbid mononitrate | Isosorbide mononite | Monisol | Monizol | Mono mack | Mono rom | Monocinque | Monolong | Mononit | Monosan | Olicard | Olicard 60 | Pectrol | Pektrol</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Ismo | Mono mack | Monorem</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Fem-mono | Imdur | Ismo | Ismo retard | Isodur | Isomex | Isonova | Isosorbidmononitrat astimex | Isosorbidmononitrat ebb | Isosorbidmononitrat Ivax | Isosorbidmononitrat Merck NM | Isosorbidmononitrat mylan | Monoket</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Elantan | Imdex CR | Imdur | Ismo</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Isocard | Mono 5-Wolff | Monosan | Olicard | Plodin</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Imdur | Mono mack | Monosan | Monosor | Monotab | Olicard | Sorbimon</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Elantan | Imdex | Imdur | Is 5 mono-ratiopharm | Ismo | Isopen | Mono mack | Monolin | Monotrate | Pentacard | Sorbinate | Vasotrate</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Monicor</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Isorat | Monodur | Monodur durules | Monoket</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Corangin | Coxine | Duride | Elantan | Ibimo | Imdur | Insure | Is 5 Mono Ratiopharm | Ismn | Ismo | Isormol | Sordur | Usomono</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Cardix | Isomonit | Isomonit retard | Mononit | Mononitrosid | Monosan | Monotrat | Olicard | Olicard retard | Plodin</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Ismo | Medocor | Mono-Conducil | Monoket</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Elantan | Ismo | Monomack | Mononitrato de isosorbide</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Donox | Imidu</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Angitrate | Elantan | Imdur | Ismo | Monicor</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Monit</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-33850272">
<a name="33850272"></a>Abad Pérez D, García Polo I, Rodríguez Salvanés FJ, Bellisco Roncal S, Ibáñez Sanz P, Suárez Fernández C. Sustained-release isosorbide mononitrate as adjuvant treatment in isolated systolic hypertension in the elderly. <i>J Hum Hypertens</i>. 2022;36(2):163-170. doi:10.1038/s41371-021-00498-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isosorbide-mononitrate-drug-information/abstract-text/33850272/pubmed" id="33850272" target="_blank">33850272</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35803111">
<a name="35803111"></a>Abu-Zaid A, Alshahrani MS, Al-Matary A, et al. Isosorbide mononitrate for cervical ripening during labour induction: a systematic review and meta-analysis of 23 randomized controlled trials.<i> Eur J Obstet Gynecol Reprod Biol</i>. 2022;276:38-46. doi:10.1016/j.ejogrb.2022.06.028<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isosorbide-mononitrate-drug-information/abstract-text/35803111/pubmed" id="35803111" target="_blank">35803111</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19623003">
<a name="19623003"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG practice bulletin no. 107: induction of labor. <i>Obstet Gynecol.</i> 2009;114(2 Pt 1):386-397. doi:10.1097/AOG.0b013e3181b48ef5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isosorbide-mononitrate-drug-information/abstract-text/19623003/pubmed" id="19623003" target="_blank">19623003</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25249585">
<a name="25249585"></a>Amsterdam EA, Wenger NK, Brindis RG, et al; ACC/AHA task force members. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. <i>Circulation</i>. 2014;130(25):e344-e426. doi:10.1161/CIR.0000000000000134<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isosorbide-mononitrate-drug-information/abstract-text/25249585/pubmed" id="25249585" target="_blank">25249585</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17692738">
<a name="17692738"></a>Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (writing committee to revise the 2002 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. <i>J Am Coll Cardiol. </i>2007;50(7):e1-e157. doi:10.1016/j.jacc.2007.02.013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isosorbide-mononitrate-drug-information/abstract-text/17692738/pubmed" id="17692738" target="_blank">17692738</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8482456">
<a name="8482456"></a>Angelico M, Carli L, Piat C, et al. Isosorbide-5-mononitrate versus propranolol in the prevention of first bleeding in cirrhosis. <i>Gastroenterology</i>. 1993;104(5):1460-1465. doi:10.1016/0016-5085(93)90356-h<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isosorbide-mononitrate-drug-information/abstract-text/8482456/pubmed" id="8482456" target="_blank">8482456</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.1">
<a name="Aronoff.1"></a>Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children.</i> 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20331608">
<a name="20331608"></a>Bagdy G, Riba P, Kecskeméti V, Chase D, Juhász G. Headache-type adverse effects of NO donors: vasodilation and beyond. <i>Br J Pharmacol</i>. 2010;160(1):20-35. doi:10.1111/j.1476-5381.2010.00643.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isosorbide-mononitrate-drug-information/abstract-text/20331608/pubmed" id="20331608" target="_blank">20331608</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9935041">
<a name="9935041"></a>Cheitlin MD, Hutter AM Jr, Brindis RG, et al. ACC/AHA expert consensus document. Use of sildenafil (<i>Viagra</i>) in patients with cardiovascular disease. American College of Cardiology/American Heart Association. <i>J Am Coll Cardiol.</i> 1999;33(1):273-282. doi:10.1016/s0735-1097(98)00656-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isosorbide-mononitrate-drug-information/abstract-text/9935041/pubmed" id="9935041" target="_blank">9935041</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11037739">
<a name="11037739"></a>Christiansen I, Iversen HK, Olesen J. Headache characteristics during the development of tolerance to nitrates: pathophysiological implications. <i>Cephalalgia</i>. 2000;20(5):437-444. doi:10.1046/j.1468-2982.2000.00064.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isosorbide-mononitrate-drug-information/abstract-text/11037739/pubmed" id="11037739" target="_blank">11037739</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18521538">
<a name="18521538"></a>Christiansen I, Iversen HK, Olesen J, Tfelt-Hansen P. Nitric oxide-induced headache may arise from extracerebral arteries as judged from tolerance to isosorbide-5-mononitrate. <i>J Headache Pain</i>. 2008;9(4):215-120. doi:10.1007/s10194-008-0043-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isosorbide-mononitrate-drug-information/abstract-text/18521538/pubmed" id="18521538" target="_blank">18521538</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23917809">
<a name="23917809"></a>Chrysant SG. Effectiveness and safety of phosphodiesterase 5 inhibitors in patients with cardiovascular disease and hypertension. <i>Curr Hypertens Rep</i>. 2013;15(5):475-483. doi:10.1007/s11906-013-0377-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isosorbide-mononitrate-drug-information/abstract-text/23917809/pubmed" id="23917809" target="_blank">23917809</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8686962">
<a name="8686962"></a>Cleophas TJ, Niemeyer MC, van der Wall EE, van der Meulen J. Nitrate-induced headache in patients with stable angina pectoris: beneficial effect of starting on a low dosage. 5-ISMN headache study group. <i>Angiology</i>. 1996;47(7):679-685. doi:10.1177/000331979604700707<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isosorbide-mononitrate-drug-information/abstract-text/8686962/pubmed" id="8686962" target="_blank">8686962</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Colucci.2019">
<a name="Colucci.2019"></a>Colucci WS. Secondary pharmacologic therapy in heart failure with reduced ejection fraction (HFrEF) in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. Accessed November 8, 2019. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-822962">
<a name="822962"></a>Come PC, Pitt B. Nitroglycerin-induced severe hypotension and bradycardia in patients with acute myocardial infarction. <i>Circulation</i>. 1976;54(4):624-628. doi:10.1161/01.cir.54.4.624<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isosorbide-mononitrate-drug-information/abstract-text/822962/pubmed" id="822962" target="_blank">822962</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24809331">
<a name="24809331"></a>Duckitt K, Thornton S, O'Donovan OP, Dowswell T. Nitric oxide donors for treating preterm labour. <i>Cochrane Database Syst Rev</i>. 2014;2014(5):CD002860. doi:10.1002/14651858.CD002860.pub2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isosorbide-mononitrate-drug-information/abstract-text/24809331/pubmed" id="24809331" target="_blank">24809331</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2506059">
<a name="2506059"></a>Emanuelsson H, Ake H, Kristi M, Arina R. Effects of diltiazem and isosorbide-5-mononitrate, alone and in combination, on patients with stable angina pectoris. <i>Eur J Clin Pharmacol</i>. 1989;36(6):561-566. doi:10.1007/BF00637736<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isosorbide-mononitrate-drug-information/abstract-text/2506059/pubmed" id="2506059" target="_blank">2506059</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3622599">
<a name="3622599"></a>Evers J, Bonn R, Boertz A, et al. Pharmacokinetics of isosorbide-5-nitrate during haemodialysis and peritoneal dialysis. <i>Eur J Clin Pharmacol.</i> 1987;32(5):503-505. doi:10.1007/BF00637678<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isosorbide-mononitrate-drug-information/abstract-text/3622599/pubmed" id="3622599" target="_blank">3622599</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3732374">
<a name="3732374"></a>Evers J, Krakamp B, Klimkait W, et al. Pharmacokinetics of isosorbide-5-nitrate in renal failure. <i>Eur J Clin Pharmacol</i>. 1986;30(3):349-350. doi:10.1007/BF00541542<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isosorbide-mononitrate-drug-information/abstract-text/3732374/pubmed" id="3732374" target="_blank">3732374</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3000161">
<a name="3000161"></a>Flaherty JT. Hemodynamic attenuation and the nitrate dose-free interval: Alternative dosing strategies for transdermal nitroglycerin. <i>Am J Cardiol.</i> 1985;56(17):321-371. doi:10.1016/0002-9149(85)90706-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isosorbide-mononitrate-drug-information/abstract-text/3000161/pubmed" id="3000161" target="_blank">3000161</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8055999">
<a name="8055999"></a>Flather M, Pipilis A, Collins R, et al. Randomized controlled trial of oral captopril, of oral isosorbide mononitrate and of intravenous magnesium sulphate started early in acute myocardial infarction: safety and haemodynamic effects. ISIS-4 (Fourth International Study of Infarct Survival) Pilot Study Investigators. <i>Eur Heart J</i>. 1994;15(5):608-619. doi:10.1093/oxfordjournals.eurheartj.a060556<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isosorbide-mononitrate-drug-information/abstract-text/8055999/pubmed" id="8055999" target="_blank">8055999</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23166211">
<a name="23166211"></a>Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. <i>Circulation. </i>2012;126(25):3097-30137. doi:10.1161/CIR.0b013e318277d6a0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isosorbide-mononitrate-drug-information/abstract-text/23166211/pubmed" id="23166211" target="_blank">23166211</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11606504">
<a name="11606504"></a>García-Pagán JC, Villanueva C, Vila MC, et al; MOVE Group. Mononitrato Varices Esofágicas. Isosorbide mononitrate in the prevention of first variceal bleed in patients who cannot receive beta-blockers. <i>Gastroenterology</i>. 2001;121(4):908-914.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isosorbide-mononitrate-drug-information/abstract-text/11606504/pubmed" id="11606504" target="_blank">11606504</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27918616">
<a name="27918616"></a>Ghosh A, Lattey KR, Kelly AJ. Nitric oxide donors for cervical ripening and induction of labour. <i>Cochrane Database Syst Rev</i>. 2016;12(12):CD006901. doi:10.1002/14651858.CD006901.pub3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isosorbide-mononitrate-drug-information/abstract-text/27918616/pubmed" id="27918616" target="_blank">27918616</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10188765">
<a name="10188765"></a>Gunasekara NS, Noble S, Isosorbide 5-Mononitrate - a review of a sustained-release formulation (Imdur) in stable angina pectoris. <i>Drugs</i>. 1999;57(2):261-277. doi:10.2165/00003495-199957020-00016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isosorbide-mononitrate-drug-information/abstract-text/10188765/pubmed" id="10188765" target="_blank">10188765</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11740135">
<a name="11740135"></a>Hall R, Chong C. A double-blind, parallel-group study of amlodipine versus long-acting nitrate in the management of elderly patients with stable angina. <i>Cardiology</i>. 2001;96(2):72-77. doi:10.1159/000047392<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isosorbide-mononitrate-drug-information/abstract-text/11740135/pubmed" id="11740135" target="_blank">11740135</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11738322">
<a name="11738322"></a>Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: Executive summary. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (committee to revise the 1995 guidelines for the evaluation and management of heart failure). <i>J Am Coll Cardiol.</i> 2001;38(7):2101-2113. doi:10.1016/s0735-1097(01)01683-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isosorbide-mononitrate-drug-information/abstract-text/11738322/pubmed" id="11738322" target="_blank">11738322</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Imdur.1">
<a name="Imdur.1"></a>Imdur (isosorbide mononitrate) [product monograph]. Mississauga, Ontario, Canada: Juno Pharmaceuticals Corp; September 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Isosorbide.1">
<a name="Isosorbide.1"></a>Isosorbide mononitrate tablets [prescribing information]. Parsippany, NJ: Actavis Pharma Inc; January 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Isosorbide.2">
<a name="Isosorbide.2"></a>Aurobindo (isosorbide mononitrate) extended-release tablets, USP [prescribing information]. East Windsor, NJ: Pharma USA Inc; June 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15533876">
<a name="15533876"></a>Kloner RA. Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction. <i>Circulation</i>. 2004;110(19):3149-3155. doi:10.1161/01.CIR.0000146906.42375.D3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isosorbide-mononitrate-drug-information/abstract-text/15533876/pubmed" id="15533876" target="_blank">15533876</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10393392">
<a name="10393392"></a>Lewis BS, Rabinowitz B, Schlesinger Z, et al. Effect of isosorbide-5-mononitrate on exercise performance and clinical status in patients with congestive heart failure. Results of the Nitrates in Congestive Heart Failure (NICE) study. <i>Cardiology</i>. 1999;91(1):1-7. doi:10.1159/000006870<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isosorbide-mononitrate-drug-information/abstract-text/10393392/pubmed" id="10393392" target="_blank">10393392</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22849337">
<a name="22849337"></a>Lo GH, Chen WC, Wang HM, Yu HC. Randomized, controlled trial of carvedilol versus nadolol plus isosorbide mononitrate for the prevention of variceal rebleeding. <i>J Gastroenterol Hepatol</i>. 2012;27(11):1681-1687. doi:10.1111/j.1440-1746.2012.07244.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isosorbide-mononitrate-drug-information/abstract-text/22849337/pubmed" id="22849337" target="_blank">22849337</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6443349">
<a name="6443349"></a>Marten W, Weiss M, Haase W. Treatment of coronary heart disease with isosorbide mononitrate ('Elantan' 20): a multi-centre study in hospital and general practice. <i>Curr Med Res Opin</i>. 1984;9(2):96-106. doi:10.1185/03007998409109566<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isosorbide-mononitrate-drug-information/abstract-text/6443349/pubmed" id="6443349" target="_blank">6443349</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37464260">
<a name="37464260"></a>McDougall ARA, Hastie R, Goldstein M, et al. New medicines for spontaneous preterm birth prevention and preterm labour management: landscape analysis of the medicine development pipeline. <i>BMC Pregnancy Childbirth.</i> 2023;23(1):525. doi:10.1186/s12884-023-05842-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isosorbide-mononitrate-drug-information/abstract-text/37464260/pubmed" id="37464260" target="_blank">37464260</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Meyer.1">
<a name="Meyer.1"></a>Meyer TE. Primary pharmacologic therapy of heart failure with reduced ejection fraction in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. Accessed October 24, 2019. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19349588">
<a name="19349588"></a>Mussi C, Ungar A, Salvioli G, et al; Evaluation of Guidelines in Syncope Study 2 Group. Orthostatic hypotension as cause of syncope in patients older than 65 years admitted to emergency departments for transient loss of consciousness. <i>J Gerontol A Biol Sci Med Sci</i>. 2009;64(7):801-806. doi:10.1093/gerona/glp028<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isosorbide-mononitrate-drug-information/abstract-text/19349588/pubmed" id="19349588" target="_blank">19349588</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35438865">
<a name="35438865"></a>National Institute for Health and Care Excellence (NICE). Inducing labour. https://www.nice.org.uk/guidance/ng207. Published November 4, 2021. Accessed November 8, 2023.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isosorbide-mononitrate-drug-information/abstract-text/35438865/pubmed" id="35438865" target="_blank">35438865</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20956226">
<a name="20956226"></a>O’Connor RE, Brady W, Brooks SC, et al. Part 10: Acute coronary syndromes: 2010 American Heart Association care guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. <i>Circulation.</i> 2010;122(18; suppl 3):787-817. doi:10.1161/CIRCULATIONAHA.110.971028<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isosorbide-mononitrate-drug-information/abstract-text/20956226/pubmed" id="20956226" target="_blank">20956226</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23256914">
<a name="23256914"></a>O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. <i>J Am Coll Cardiol</i>. 2013;61(4):e78-e140. doi:10.1016/j.jacc.2012.11.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isosorbide-mononitrate-drug-information/abstract-text/23256914/pubmed" id="23256914" target="_blank">23256914</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33229116">
<a name="33229116"></a>Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>J Am Coll Cardiol</i>. 2020;76(25):e159-e240. doi:10.1016/j.jacc.2020.08.045<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isosorbide-mononitrate-drug-information/abstract-text/33229116/pubmed" id="33229116" target="_blank">33229116</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8213541">
<a name="8213541"></a>Parker JO. Eccentric dosing with isosorbide-5-mononitrate in angina pectoris. <i>Am J Cardiol.</i> 1993;72(12):871-876. doi:10.1016/0002-9149(93)91098-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isosorbide-mononitrate-drug-information/abstract-text/8213541/pubmed" id="8213541" target="_blank">8213541</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3574424">
<a name="3574424"></a>Parker JO, Fanell B, Lahey KA, Moe G. Effect of intervals between doses on the development to tolerance to isosorbide dinitrate. <i>N Engl J Med.</i> 1987;316(23):1440-1444. doi:10.1056/NEJM198706043162303<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isosorbide-mononitrate-drug-information/abstract-text/3574424/pubmed" id="3574424" target="_blank">3574424</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8509566">
<a name="8509566"></a>Pipilis A, Flather M, Collins R, et al. Hemodynamic effects of captopril and isosorbide mononitrate started early in acute myocardial infarction: a randomized placebo-controlled study. <i>J Am Coll Cardiol</i>. 1993;22(1):73-79. doi:10.1016/0735-1097(93)90817-k<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isosorbide-mononitrate-drug-information/abstract-text/8509566/pubmed" id="8509566" target="_blank">8509566</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18514825">
<a name="18514825"></a>Rangel-Castilla L, Gopinath S, Robertson CS. Management of intracranial hypertension. <i>Neurol Clin</i>. 2008;26(2):521-541, x. doi:10.1016/j.ncl.2008.02.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isosorbide-mononitrate-drug-information/abstract-text/18514825/pubmed" id="18514825" target="_blank">18514825</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9727544">
<a name="9727544"></a>Rinaldi CA, Linka AZ, Masani ND, et al. Randomized, double-blind crossover study to investigate the effects of amlodipine and isosorbide mononitrate on the time course and severity of exercise-induced myocardial stunning. <i>Circulation</i>. 1998;98(8):749-756. doi:10.1161/01.cir.98.8.749<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isosorbide-mononitrate-drug-information/abstract-text/9727544/pubmed" id="9727544" target="_blank">9727544</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12574098">
<a name="12574098"></a>Stokes GS, Barin ES, Gilfillan KL. Effects of isosorbide mononitrate and AII inhibition on pulse wave reflection in hypertension. <i>Hypertension</i>. 2003;41(2):297-301. doi:10.1161/01.hyp.0000049622.07021.4f<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isosorbide-mononitrate-drug-information/abstract-text/12574098/pubmed" id="12574098" target="_blank">12574098</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3595067">
<a name="3595067"></a>Thadani U, Prasad R, Hamilton SF, et al. Isosorbide-5-mononitrate in angina pectoris: Plasma concentrations and duration of effects after acute therapy. <i>Clin Pharmacol Ther.</i> 1987;42(1):58-65. doi:10.1038/clpt.1987.108<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isosorbide-mononitrate-drug-information/abstract-text/3595067/pubmed" id="3595067" target="_blank">3595067</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11547718">
<a name="11547718"></a>Villaneuva C, Minana J, Ortiz J, et al. Endoscopic litigation compared with combined treatment with nadolol and isosorbide mononitrate to prevent recurrent variceal bleeding. <i>N Engl J Med.</i> 2001;345(9):647-655. doi:10.1056/NEJMoa003223<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isosorbide-mononitrate-drug-information/abstract-text/11547718/pubmed" id="11547718" target="_blank">11547718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8682597">
<a name="8682597"></a>Walker JM, Curry PV, Bailey AE, Steare SE. A comparison of nifedipine once daily (<i>Adalat LA</i>), isosorbide mononitrate once daily, and isosorbide dinitrate twice daily in patients with chronic stable angina. <i>Int J Cardiol</i>. 1996;53(2):117-126. doi:10.1016/0167-5273(95)02531-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isosorbide-mononitrate-drug-information/abstract-text/8682597/pubmed" id="8682597" target="_blank">8682597</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11409656">
<a name="11409656"></a>Wang H, Hu D, Sun N, Gong L, Zhang W. Effect of long-acting isosorbide-5-mononitrate administration on large artery distensibility in patients with essential hypertension. <i>Hypertens Res</i>. 2001;24(3):311-4. doi:10.1291/hypres.24.311<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isosorbide-mononitrate-drug-information/abstract-text/11409656/pubmed" id="11409656" target="_blank">11409656</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1760824">
<a name="1760824"></a>Waysbort J, Meshulam N, Brunner D. Isosorbide-5-mononitrate and atenolol in the treatment of stable exertional angina. <i>Cardiology</i>. 1991;79(suppl 2):19-26. doi:10.1159/000174920<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isosorbide-mononitrate-drug-information/abstract-text/1760824/pubmed" id="1760824" target="_blank">1760824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35947046">
<a name="35947046"></a>Wilson A, Hodgetts-Morton VA, Marson EJ, et al. Tocolytics for delaying preterm birth: a network meta-analysis (0924). <i>Cochrane Database Syst Rev.</i> 2022;8(8):CD014978. doi:10.1002/14651858.CD014978.pub2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isosorbide-mononitrate-drug-information/abstract-text/35947046/pubmed" id="35947046" target="_blank">35947046</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). WHO recommendation on tocolytic therapy for improving preterm birth outcomes. 2022. <a href="https://www.ncbi.nlm.nih.gov/books/NBK585023/" target="_blank">https://www.ncbi.nlm.nih.gov/books/NBK585023/</a>. Accessed November 8, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25790943">
<a name="25790943"></a>Wu M, Villano A, Russo G, et al. Poor tolerance and limited effects of isosorbide-5-mononitrate in microvascular angina. <i>Cardiology</i>. 2015;130(4):201-206. doi:10.1159/000370027<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isosorbide-mononitrate-drug-information/abstract-text/25790943/pubmed" id="25790943" target="_blank">25790943</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8581 Version 411.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
